To Evaluate the Efficacy and the Safety of Monthly Versus Weekly Oral Risedronate With Vitamin D in Compliance, Improvement of Vitamin D and BMD in Korean Postmenopausal Osteoporotic Women

The purpose of this study is to evaluate the Efficacy and the Safety of Monthly(RisenexM group) versus Weekly Oral risedronate(Risenexsplus group) with Vitamin D in compliance, improvement of vitaminD and BMD in Korean postmenopausal osteoporotic women(Phase IV)

Inclusion criteria

• Female osteoporosis patients over 19years of age(with menopause).

Definition of osteporosis

• They had a BMD T-score -2.5 or less at mean Lumbar spine(L1~L4), Femoral neck or total. Or evidence of at least one vertebral fracture.

Definition of menopause(can be one of three condition)

• For 12months spontaneous amenorrhea
• For 6months spontaneous amenorrhea with serum FSH(Follicle stimulating hormone) is 40 mlIU/mL and over
• 6weeks after bilateral ovariectomy whether hysterectomy of not
• Patients who can be treated with oral bisphosphonate drugs
• Patients who have adequate to be measured DXA(Dual energy x-ray absorptiometry)
• Patients who made a voluntary agreement after explanation of this study
• Patients who participated in clinical trial(HL_RSNP_401) must have taken the Risenexplus and finish the study for 12 months.

Exclusion criteria

• Patients with esophagus disorder.
• Patients administered with osteoprosis therapy(except calcium,Vit.D medication) within previous 3 months
• Patients with serum calcium concentrations 8.0mg/dL under.
• Patients with severe nephropathy(serum creatinine> doulble of normal level
• Patients with unable to sit upright or stand 30minutes.